Delstrigo
The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.
Delstrigo is a once-daily, fixed-dose, combination tablet of doravirine, lamivudine and tenofovir for the treatment of HIV-1 in adult patients with no prior antiretroviral treatment experience.
Delstrigo Overview
Delstrigo is a prescription medicine that is used without other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults who have not taken HIV-1 medicines before. It is a single product containing 3 medications: doravirine, lamivudine, and tenofovir disoproxil fumarate.
Delstrigo belongs to a group of drugs called antiretrovirals, more specifically non-nucleoside reverse transcriptase inhibitors (NNRTI) as well as nucleoside analogue reverse transcriptase inhibitors (NRTIs). These help to block essential enzymes needed by HIV to make copies of itself.
This medication comes in tablet form and is taken once a day, with or without food.
Common side effects of Delstrigo include nausea, and abnormal dreams. Delstrigo can also cause dizziness. Do not drive or operate heavy machinery until you know how Delstrigo affects you.
How was your experience with ?
Delstrigo Drug Class
Delstrigo is part of the drug class:
Delstrigo FDA Warning
WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B
Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued lamivudine or tenofovir disoproxil fumarate (TDF), which are components of DELSTRIGO. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue DELSTRIGO. If appropriate, initiation of anti-hepatitis B therapy may be warranted.